$33.18
0.18% today
Nasdaq, Apr 03, 06:49 pm CET
ISIN
US52490G1022
Symbol
LEGN
Sector
Industry

Legend Biotech Corp - ADR Stock price

$33.24
+0.26 0.79% 1M
-15.44 31.72% 6M
+0.70 2.15% YTD
-23.19 41.10% 1Y
-6.24 15.81% 3Y
-3.76 10.16% 5Y
-3.76 10.16% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+1.72 5.46%
ISIN
US52490G1022
Symbol
LEGN
Sector
Industry

Key metrics

Market capitalization $6.10b
Enterprise Value $5.33b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 8.50
P/S ratio (TTM) P/S ratio 9.73
P/B ratio (TTM) P/B ratio 5.87
Revenue growth (TTM) Revenue growth 119.97%
Revenue (TTM) Revenue $627.24m
EBIT (operating result TTM) EBIT $-309.57m
Free Cash Flow (TTM) Free Cash Flow $-210.32m
Cash position $1.12b
EPS (TTM) EPS $-0.97
P/E forward negative
P/S forward 5.94
EV/Sales forward 5.19
Short interest 11.91%
Show more

Is Legend Biotech Corp - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Legend Biotech Corp - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Legend Biotech Corp - ADR forecast:

24x Buy
92%
2x Hold
8%

Analyst Opinions

26 Analysts have issued a Legend Biotech Corp - ADR forecast:

Buy
92%
Hold
8%

Financial data from Legend Biotech Corp - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
627 627
120% 120%
100%
- Direct Costs 258 258
67% 67%
41%
369 369
162% 162%
59%
- Selling and Administrative Expenses 242 242
27% 27%
39%
- Research and Development Expense 414 414
8% 8%
66%
-286 -286
-
-46%
- Depreciation and Amortization 23 23
-
4%
EBIT (Operating Income) EBIT -310 -310
30% 30%
-49%
Net Profit -177 -177
66% 66%
-28%

In millions USD.

Don't miss a Thing! We will send you all news about Legend Biotech Corp - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Legend Biotech Corp - ADR Stock News

Neutral
Seeking Alpha
23 days ago
Legend Biotech Corporation (NASDAQ:LEGN ) Q4 2024 Earnings Conference Call March 11, 2025 8:00 AM ET Company Participants Caroline Paul - Associate Director, IR Ying Huang - CEO Jessie Yeung - Interim CFO Mythili Koneru - Chief Medical Officer Guowei Fang - President, R&D Alan Bash - President, CARVYKTI Conference Call Participants Jon Miller - Evercore Hang Hu - Barclays Yaron Werber - TD Cowe...
Neutral
GlobeNewsWire
23 days ago
SOMERSET, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported financial results for the fourth quarter and year ended December 31, 2024, and key corporate highlights.
Positive
Seeking Alpha
3 months ago
Legend Biotech is a commercial-stage biotech company specializing in innovative cell therapies, with a strong pipeline and global R&D presence. LEGN's flagship product, CARVYKTI, has received multiple regulatory approvals and shows significant sales growth, with potential peak sales of at least $3B. The company has an impressive pipeline (with 11 non-CARVYKTI related programs), high growth rate...
More Legend Biotech Corp - ADR News

Company Profile

Legend Biotech Corporation develops cell therapy solutions for cancer patients. The company was founded in 2014 and is based in Cayman Islands. The company operates as a subsidiary of Genscript Biotech Corporation.

Head office Cayman Islands
CEO Ying Huang
Employees 2,609
Founded 2014
Website www.legendbiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today